Consensus $8.28. Backs FY23 revenue view $30.3B-$30.8B, consensus $30.55B. Sees FY23 tax rate 13%. Sees FY23 gross margin as a percent of revenue 79%. Anat Ashkenazi, Lilly’s executive vice president and chief financial officer added: "As we closed out 2022, Lilly demonstrated strong growth and achieved meaningful pipeline progress that included the launch for Mounjaro in type 2 diabetes. We expect to capitalize on this momentum and deliver mid-teen revenue growth for our core business in 2023 while remaining committed to investing in innovation, late-stage opportunities, manufacturing capacity, and our people."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on LLY:
- Pharma Earnings: Q4 Hits and Misses in a Post-COVID-19 World
- Eli Lilly says FDA approves Jaypirca
- Eli Lilly to invest $450M to expand manufacturing at Research Triangle Park
- Eli Lilly, Boehringer: FDA accepts sNDA for Jardiance for adults with CKD
- Donanemab CRL a ‘positive headline’ for Biogen’s Leqembi, says William Blair
